Nidani, a small molecule tyrosine kinase inhibitor (TKI), was developed by Boehringer Ingelheim Company to treat idiopathic pulmonary fibrosis (IPF). The drug acts on the growth factor receptor which has been proved to have potential influence on the pathological mechanism of pulmonary fibrosis.
Baidu search natcocn can be found.